AXIM Biotechnologies Featured in Marijuana Documentary “Cannabis is Medicine”

Documentary Features World Leaders in Cannabis Research, Explains AXIM® Biotech’s Clinical Trials on Patented Cannabinoid Release Chewing Gum for Pain and Spasticity in Multiple Sclerosis

New York, New York, UNITED STATES

NEW YORK, Jan. 13, 2016 (GLOBE NEWSWIRE) -- AXIM® Biotechnologies, Inc. (OTC:AXIM) is pleased to announce that the Company’s efforts on clinical development of a patented cannabinoid-based medical chewing gum will be featured in a documentary to be released in the first quarter of 2016. The documentary Cannabis is Medicine is produced by Jordan Guzzardo, Emmy award-winning documentarian and photojournalist.

Cannabis is Medicine features the compelling personal stories of individuals with different symptoms and conditions who have benefitted from AXIM's products. From New York to the Netherlands, the documentary interviews international leaders in cannabinoid sciences and regulatory authorities who discuss the medical benefits as well as the legal, political and clinical hurdles faced while bringing to market the world’s first patented controlled-release cannabinoid chewing gum, MedChew Rx™.

AXIM® Biotech is focused upon unique proprietary delivery mechanisms for the introduction of cannabinoids (i.e. THC, CBD, CBG, CBN, etc.) and finding solutions for conditions for which there is currently no effective treatment including: MS, spasticity, pain, Parkinson’s disease, Alzheimer’s disease/dementia, ADHD (attention deficit hyperactivity disorder), psychosis, PTSD, autism, RLS (restless leg syndrome), glaucoma, IBD, IBS, and Crohn’s disease.

The documentary is scheduled for release in March 2016 and is anticipated to be submitted to multiple national and international film festivals.

AXIM® Biotech has been featured by media outlets including: Reuters, Yahoo! Finance, Marketwatch, ABC, NBC, CBS, Telemundo, WGN, Univision, Marijuana Investor News, FOX Business,, MJ Freeway, Chemical & Engineering News, Dental Tribune, Pharmaceutical Commerce, Dental Products Report and MJI News. For more information, visit AXIM Biotech’s website.

To arrange for media interviews, contact Andrew Hard, Public Relations Spokesperson, at or call 888-829-0070.

About AXIM Biotechnologies:
AXIM Biotechnologies (OTC: AXIM) is an innovative biotechnology company focusing on research, development and production of pharmaceutical, nutraceutical and cosmetic products where we prioritize the well-being of our customers while embracing a solid fiscal strategy.  For more information, visit the Company website at

This press release may contain certain forward-looking statements and information, as defined within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and is subject to the Safe Harbor created by those sections. This material contains statements about expected future events and/or financial results that are forward-looking in nature and subject to risks and uncertainties. Such forward-looking statements by definition involve risks, uncertainties and other factors, which may cause the actual results, performance or achievements of Axim Biotechnologies, Inc. to be materially different from the statements made herein.

AXIM Biotechnologies does not sell or distribute any products that are in violation of the United States Controlled Substances Act (US.CSA). The company does sell and distribute hemp-based products.


Contact Data